Navigating Pharma Changes in 2025: The Future of Off-Label Promotion
Join AFS Life Sciences Partner Stephanie Trunk and Darshan Kulkarni, Life Sciences regulatory and compliance attorney, as they explore the major shifts occurring in the pharmaceutical industry under the Trump Administration.
On
Highlights of the conversation include:
- Evolving regulations for off-label pharmaceutical promotion.
- Enhancing a firm’s global footprint by building trust with sovereign governments.
- Examining new compliance challenges stemming from AI technology.
- Navigating US Food and Drug Administration guidance as an unreliable indicator of enforcement priorities.
- Increasing scrutiny of the role of medical affairs.
- Finding balance between patient access and regulatory compliance.
Contacts
- Related Industries